Sundaram Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.15 M
as on 16-11-2024
- Company Age 20 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.50 Cr
as on 16-11-2024
- Revenue 114.03%
(FY 2023)
- Profit 152.51%
(FY 2023)
- Ebitda 164.98%
(FY 2023)
- Net Worth 78.12%
(FY 2023)
- Total Assets 109.26%
(FY 2023)
About Sundaram Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.15 M.
The company currently has active open charges totaling ₹3.50 Cr.
Dinesh Singh, Brijesh Singh, and Dhroov Singh serve as directors at the Company.
- CIN/LLPIN
U51397MH2004PTC149475
- Company No.
149475
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Nov 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sundaram Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Singh  | Director | 01-May-2023 | Current |
| Brijesh Singh | Director | 09-Nov-2004 | Current |
| Dhroov Singh | Director | 15-Mar-2022 | Current |
Financial Performance of Sundaram Pharma.
Sundaram Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 114.03% increase. The company also saw a substantial improvement in profitability, with a 152.51% increase in profit. The company's net worth Soared by an impressive increase of 78.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sundaram Pharma?
In 2023, Sundaram Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Prevego Healthcare & Research Private LimitedActive 6 years 7 monthsBrijesh Singh is a mutual person
Chandra-Corbox Packaging Private LimitedActive 27 years 5 monthsDinesh Singh and Brijesh Singh are mutual person
- Satyam Generic Pharma Private LimitedActive 24 years 24 days
Dinesh Singh, Brijesh Singh and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 08 Apr 2024 | ₹3.50 Cr | Open |
How Many Employees Work at Sundaram Pharma?
Unlock and access historical data on people associated with Sundaram Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sundaram Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sundaram Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
